Steven Pipe, Professor of Pediatrics and Pathology at the University of Michigan, explained: “The five-year HOPE-B results ...

Enterprise Therapeutics has announced the publication of results from its phase 1 study of ETD001, a long-acting inhaled ...

Johnson & Johnson has welcomed the decision by the Scottish Medicines Consortium (SMC) to accept Rybrevant (amivantamab) in combination with carboplatin and pemetrexed for use within NHS Scotland as a ...

Johnson & Johnson has announced updated results from the phase 3 CARTITUDE-4 study, showing that CARVYKTI (ciltacabtagene autoleucel; cilta-cel) can deliver durable treatment-free remissions as early ...

Bayer’s ASSESS study is a randomised, double-blind, placebo-controlled, parallel group phase 2a trial with an extension phase ...

Johnson & Johnson has received European Commission approval for nipocalimab, marketed as IMAAVY, as an add-on therapy for ...

Pharvaris has announced positive topline data from its RAPIDe-3 pivotal phase 3 study, confirming the potential of ...

AlzeCure Pharma AB has announced it has received the first payment of a EUR 2.5 million grant from the European Innovation Council (EIC). The funding will support a phase 2a clinical study of the ...

Young people are our future workforce, so it’s important that companies have a youth-positive culture. To be competitive, ...

The phase 1 trial, VNA-318-01, was a randomized, double-blind study involving 92 healthy male subjects. Interim results ...

Draig Therapeutics has announced the appointment of Ivana Magovčević-Liebisch as President and Chief Executive Officer. She ...

SERB Pharmaceuticals has appointed Dr Vignesh Rajah as its new Chief Medical Officer, bringing over 20 years of global ...